Evidence map›Paper›PMID 37396490›Full record

ArticleEuropean journal of radiology open2023

Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer.

Lin Li, Rakesh Shiradkar, Sree Harsha Tirumani, Leonardo Kayat Bittencourt, Pingfu Fu, Amr Mahran, Christina Buzzy, Phillip D Stricker, Ardeshir R Rastinehad, Cristina Magi-Galluzzi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of radiology open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin LiCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Rakesh ShiradkarCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Sree Harsha TirumaniDepartment of Radiology, University Hospitals, Cleveland, OH, USA.
Leonardo Kayat BittencourtDepartment of Radiology, University Hospitals, Cleveland, OH, USA.
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.
Amr MahranUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Christina BuzzyCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Phillip D StrickerDepartment of Urology, St. Vincent's Clinic, Sydney, NSW 2010, Australia.
Ardeshir R RastinehadDepartment of Urology, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Cristina Magi-GalluzziDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Lee PonskyUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Eric KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Andrei S PuryskoGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: around one third of clinically significant prostate cancer (CsPCa) foci are reported to be MRI non-visible (MRI─). Objective: To quantify the differences between MR visible (MRI+) and MRI Methods: This retrospective and multi-institutional study comprised 164 patients with pre-biopsy 3T prostate multi-parametric MRI from 2014 to 2017. The MRI Results: Both intra-lesional and peri-lesional bpMRI Haralick and CoLlAGe radiomic features were significantly associated with MRI Conclusion: Our preliminary results demonstrated that both intra-lesional and peri-lesional bpMRI radiomic features were significantly associated with MRI

Indexed as

Clinically significant prostate cancerMR non-visibleRadiomic

Identifiers

PMID37396490
PMCPMC10311200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.